XNCR 241220 17.50P (XNCR241220P17500) Stock Options, News & Quotes

US OptionsDetailed Quotes

XNCR241220P17500

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Xencor Reports Q3 2024 Earnings and Program Updates
TipRanksNov 20 22:53 ET
Top Premarket Gainers
MT NewswiresNov 19 07:39 ET
Xencor Insider Sold Shares Worth $1,612,639, According to a Recent SEC Filing
MT NewswiresNov 13 17:59 ET
Barclays Maintains Xencor(XNCR.US) With Sell Rating, Maintains Target Price $22
Moomoo NewsNov 9 06:33 ET · Ratings
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $22 to $34
Moomoo NewsNov 8 08:00 ET · Ratings
Barclays Sticks to Its Sell Rating for Xencor (XNCR)
TipRanksNov 8 04:51 ET · Ratings

Comments

Moomoo AI

Mar 10 07:41

Bassil Dahiyat's recent sale of Xencor shares is the largest insider sale in the past year. It's discouraging when insiders sell below the current price, suggesting satisfaction with a lower valuation. Despite insider ownership, caution is advised due to sales history.

Don't Ignore The Insider Selling In Xencor

Moomoo AI

Mar 7 05:47

Xencor's share price rise doesn't match its P/S ratio, likely due to weaker forecast growth than the industry. These conditions may continue to limit the share price.

Improved Revenues Required Before Xencor, Inc. (NASDAQ:XNCR) Stock's 27% Jump Looks Justified

Moomoo AI

Feb 5 13:56

Xencor's lack of profitability and uninspiring revenue growth, despite its pursuit of growth, may have led to its share price decline. Investors may question its long-term viability with continued weak revenue growth and unprofitability.

Xencor (NASDAQ:XNCR Shareholders Incur Further Losses as Stock Declines 8.5% This Week, Taking Three-year Losses to 65%

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...